Archive for the ‘japan retractions’ Category
In this Japanese population with a high baseline fracture risk, combined treatment with folate and vitamin B12 is safe and effective in reducing the risk of a hip fracture in elderly patients following stroke.
There’s been a 10th retraction from two former postdocs at a UT-Southwestern cancer research center who were sanctioned by the Office of Research Integrity (ORI) last September, in part due to observations and comments from Retraction Watch readers.
It’s a 2008 Cancer Letters paper, “Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer,” retracted at the request of Makoto Suzuki, the first author who has claimed responsibility for falsifying data in this and five other papers. Read the rest of this entry »
Following an investigation into research misconduct, the Journal of Clinical Investigation has retracted a cancer genetics paper from a laboratory at the National Institutes of Health due to “data falsification and fabrication” of four figures and a table in the paper.
The paper, “FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer,” describes an overexpressed gene in mouse prostate cancers that appears to suppress immune system cells.
The journal retracted the paper following an investigation into author Stephanie K. Watkins, then a postdoctoral fellow at the National Cancer Institute. According to a NIH press release released about the study in March 2011, the work “has led to the submission of a patent application by the NIH on behalf of Hurwitz and Watkins to target FOXO3 as a way to boost immune responses in cancer and to silence excessive immune responses in autoimmune diseases.” We found an NIH record of the patent application, but no record of an approved patent at the United States Patent and Trademark Office under either Hurwitz or Watkins’ names.
Noriyuki Takai, a gynecologic cancer researcher in Japan, has notched one more retraction — bringing the total to eight — due to figures that were “processed inappropriately” and did “not accurately report the original data.”
According to the notice, Takai alone put the figures together in the 2006 Oncology paper, which tested a histone deacetylase inhibitor on endometrial and ovarian cancer cell lines. The team is part of the department of obstetrics and gynecology at Oita University in Japan.
Journal ISIJ International minced no words about why the 2014 paper on steel manufacturing was withdrawn, because there were no words. Here’s the notice for “Microstructure and Properties of Fiber Laser Welded Joints of Ultrahigh-strength Steel 22MnB5 and its Dissimilar Combination with Q235 Steel” in its entirety – half the length of the title!: Read the rest of this entry »
A new paper in the MDPI journal Publications reports that the only controlled study on the effect of giving COPD patients Omega-3 has been cited 52 times since being retracted. Of those, only two mentioned the retraction.
In 2005, Chest published an article that found that COPD patients who took omega-3 supplements for 2 years experienced improvements in their condition, such as better walking tests and a decrease in sputum cytokines. But when an institutional investigation found the lead author had falsified the data, the journal retracted the paper in 2008.
That’s news to many researchers in the field. Among the 50 papers that cited the research after 2008 without stating it had been retracted, 20 included “specific data” from the paper, while the other 30 “cited the reference in passing.” Articles citing the retracted study have themselves been cited 947 times total, pointing to the ripple effect this kind of unwitting mention can have throughout the literature.
Takeda group retracts paper after realizing “novel” compound had already been synthesized…by a colleague
A group of scientists at Takeda Pharmaceutical, including vice president Yoshinori Ikeura, has lost a paper after realizing that their “novel” compound had been previously synthesized by another Takeda researcher.
The 2011 paper, published in Elsevier journal Bioorganic & Medicinal Chemistry, was the subject of a 2012 corrigendum adding two authors to the paper. The retraction appeared online in December of this year.
Seems like they didn’t add enough authors, though. Read the rest of this entry »
Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest.
Also that year, suspicions about Chiba University hypertension researcher Issei Komuro’s work were first raised by an anonymous blog, which detailed numerous image manipulations in the researcher’s published works. Komuro, who frequently collaborated with Matsubara, has been a senior author on a number of valsartan papers, including the now-retracted one, which reported the results of Novartis-sponsored Valsartan Amlodipine Randomized Trial in 2011 without reporting the Novartis funding.
Former University of Tokyo researcher Shigeaki Kato continues to put big numbers on the board.
Last month, we reported on his 26th, 27th, and 28th retractions, all in Nature Cell Biology and cited close to 700 times. Yesterday, EMBO Journal and EMBO Reports published a total of five more retractions for the endocrinology researcher, who resigned from the university in 2012 following investigations found he had faked images.
Jaime A. Teixeira da Silva, Judit Dobránszki, Jean Carlos Cardoso, and Songjun Zeng had submitted the manuscript, “Genetic transformation of Dendrobium,” to GM Crops and Food: Biotechnology in Agriculture and the Food Chain earlier this year. It was accepted on July 29, and posted online on October 30.
Taylor and Francis — who recently took over the journal from Landes Biosciences — had requested $1,000 in page charges, and $340 in color charges. But Teixeira da Silva — who has been made persona non grata by an Elsevier journal following “personal attacks and threats,” and had a paper retracted by a Springer journal after he demanded the editors’ resignations — insisted in an email to the publisher that Read the rest of this entry »